Press Releases Novo Nordisk A/S

Equities

NOVO B

DK0062498333

Pharmaceuticals

Market Closed - Nasdaq Copenhagen Other stock markets 11:20:00 2025-07-18 EDT			5-day change	1st Jan Change
414.60 ^DKK	-2.22%		-5.55%	-33.58%

07-18	Fangzhou Inc. and Novo Nordisk Signs Collaboration Memorandum to Establish A New Ecosystem for Health Management	CI
07-18	NOVO NORDISK : UBS keeps its Buy rating	ZD

Press Releases

Canadian Investment Regulatory Organization Trade Resumption - NVON	07-18	AQ
Canadian Investment Regulatory Organization Trading Halt - NVON	07-18	AQ
Hims & Hers to bring generic semaglutide to Canada	07-09	AQ
Securities Fraud Investigation Into Novo Nordisk A/S (NVO) Announced – Investors Who Lost Money Urged To Contact Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm	06-25	BU
NVO Investors Have Opportunity to Join Novo Nordisk A/S Fraud Investigation with the Schall Law Firm	06-25	BU
Novo Nordisk A/S (NVO) Investors Who Lost Money – Contact Law Offices of Howard G. Smith About Securities Fraud Investigation	06-25	BU
Securities Fraud Investigation Into Novo Nordisk A/S (NVO) Announced – Investors Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz	06-24	BU
Novo Nordisk A/S: Ozempic® receives EU recommendation in peripheral arterial disease, cementing the broad benefits of semaglutide for people with type 2 diabetes and comorbidities	06-23	GL
Novo Nordisk ends collaboration with Hims & Hers	06-23	AQ
Novo Nordisk makes breakthrough with new weight-loss drug CagriSema	06-23	AQ
Novo Nordisk A/S: Mim8 prophylaxis treatment shown to be well-tolerated when switching from emicizumab in people with haemophilia A in new phase 3 data presented at the ISTH 2025 Congress	06-22	AQ
Novo Nordisk A/S: Mim8 prophylaxis treatment shown to be well-tolerated when switching from emicizumab in people with haemophilia A in new phase 3 data presented at the ISTH 2025 Congress	06-22	GL
Novo Nordisk A/S: CagriSema 2.4 mg / 2.4 mg demonstrated 22.7% mean weight reduction in adults with overweight or obesity in REDEFINE 1, published in New England Journal of Medicine	06-22	AQ
Novo Nordisk A/S: CagriSema 2.4 mg / 2.4 mg demonstrated 22.7% mean weight reduction in adults with overweight or obesity in REDEFINE 1, published in New England Journal of Medicine	06-22	GL
Novo Nordisk: Higher dose of Wegovy® provided average weight loss of 21% in people with obesity – with a third achieving 25% or more – according to data presented at ADA	06-20	AQ
Novo Nordisk: Higher dose of Wegovy® provided average weight loss of 21% in people with obesity – with a third achieving 25% or more – according to data presented at ADA	06-20	GL
Novo Nordisk’s subcutaneous and oral amycretin data published in The Lancet and presented at ADA 2025	06-20	AQ
Novo Nordisk’s subcutaneous and oral amycretin data published in The Lancet and presented at ADA 2025	06-20	GL
Novo Nordisk to advance subcutaneous and oral amycretin for weight management into phase 3 clinical development	06-12	GL
Deep Apple Therapeutics Announces Collaboration with Novo Nordisk to Discover and Develop Oral Therapeutics for Cardiometabolic Diseases	06-12	AQ
ADA 2025, Novo Nordisk highlights strong portfolio data with new semaglutide and CagriSema results, redefining possibilities in obesity and diabetes care	06-11	AQ
ADA 2025: Novo Nordisk highlights strong portfolio data with new semaglutide and CagriSema results, redefining possibilities in obesity and diabetes care	06-10	GL
The American Diabetes Association - The Obesity Association and Novo Nordisk Inc. are changing the Conversation on Obesity	06-04	AQ
Novo Nordisk A/S : 2025 ( conflict mineral disclosure 2025 )	06-02	PU
A Conversation With Tamer Mohamed (Video)	05-27	AQ